Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

Group 1 - Creative Medical Technology Holdings, Inc. has received a Notice of Allowance for a U.S. patent related to the treatment of Type 1 Diabetes, which will be effective until at least 2040 [1][4] - The patent supports a cell-based immunotherapy approach using the ImmCelz product, which involves supercharged T regulatory cells derived from patients with Type 1 Diabetes [2][5] - Type 1 Diabetes is characterized by the immune system attacking insulin-producing beta cells in the pancreas, leading to insulin deficiency [3] Group 2 - The CEO of Creative Medical emphasizes that the use of ImmCelz represents regenerative immunotherapy and highlights the ongoing CREATE-1 clinical trial focused on Type 1 Diabetes [4] - The ImmCelz platform reprograms a patient's immune cells with optimized cell-free factors, enhancing their regenerative properties for potential treatment of various conditions [5][6] - Creative Medical is a clinical-stage biotechnology company specializing in regenerative medicine solutions across multiple indications, including pain management and neurology [6]